1260907-17-2 | 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-4-acetamide, 6-(4-chlorophenyl)-N-ethyl-8-methoxy-1-methyl-, (4S)-

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$14.00	$10.00
2mg	98%	in stock	$17.00	$12.00
5mg	98%	in stock	$28.00	$19.00
10mg	98%	in stock	$42.00	$30.00

Description

• Catalog Number: AA35581
• Chemical Name: 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-4-acetamide, 6-(4-chlorophenyl)-N-ethyl-8-methoxy-1-methyl-, (4S)-
• CAS Number: 1260907-17-2
• Molecular Formula: C22H22ClN5O2
• Molecular Weight: 423.8954
• MDL Number: MFCD22417091
• SMILES: CCNC(=O)C[C@@H]1N=C(c2ccc(cc2)Cl)c2c(-n3c1nnc3C)ccc(c2)OC

Computed Properties

• Complexity: 639
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 2.9

Literature

• Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells.

  The Journal of biological chemistry 20180216

• The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.

  Oncogene 20170105

• MCM5 as a target of BET inhibitors in thyroid cancer cells.

  Endocrine-related cancer 20160401

• CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

  The Journal of clinical investigation 20160201

• BET inhibitor resistance emerges from leukaemia stem cells.

  Nature 20150924

• An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

  Cell research 20140701

• Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

  Molecular cancer therapeutics 20140501

• Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

  Blood 20140130

• Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.

  ACS medicinal chemistry letters 20130912

• Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.

  Journal of medicinal chemistry 20130425

• Cancer research: Open ambition.

  Nature 20120809

• From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.

  Bioorganic & medicinal chemistry letters 20120415

• Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.

  Journal of medicinal chemistry 20120126

• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  Cell 20110916

• Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.

  Biochimica et biophysica acta 20110801

• Discovery and characterization of small molecule inhibitors of the BET family bromodomains.

  Journal of medicinal chemistry 20110609

• Suppression of inflammation by a synthetic histone mimic.

  Nature 20101223